CXCR4 Receptor Compounds
AssigneeAnchor Therapeutics, Inc.
InventorsThomas J. McMurry, Athan Kuliopulos, Lidija Covic, Boris Tchernychev
Life of this patent
Estimating the term…
Loading patent…
AssigneeAnchor Therapeutics, Inc.
InventorsThomas J. McMurry, Athan Kuliopulos, Lidija Covic, Boris Tchernychev
Estimating the term…
The invention relates generally to compounds which are allosteric modulators (e.g., positive and negative allosteric modulators, and allosteric agonists) of the G protein coupled receptor for stromal derived factor 1 (SDF-I), also known as the CX-CR4 receptor. The CXCR4 receptor compounds are derived from the intracellular loops and domains of the CXCR4 receptor. The invention also relates to the use of these CXCR4 receptor compounds and pharmaceutical compositions comprising the CXCR4 receptor compounds in the treatment of diseases and conditions associated with CXCR4 modulation such as bone marrow trans-plantation, chemosensitization, cancer, metastatic disease, inflammatory diseases, HIV infection and stem cell-based regenerative medicine.
A compound represented by Formula A:
A compound represented by Formula B or a pharmaceutically acceptable salt thereof:
A compound represented by Formula C or a pharmaceutically acceptable salt thereof:
A compound represented by Formula D or a pharmaceutically acceptable salt thereof, wherein:
A compound represented by Formula I:
Dependencies are inferred from the claim text.